| 英文名稱 |
中文名稱 |
CAS號 |
操作 |
| Felzartamab |
菲澤妥單抗 |
2197112-39-1 |
詳細
|
| CCCI-01 |
5-Nitro-N-(3-pyridinylmethyl)-2-furancarboxamide |
215778-97-5 |
詳細
|
| Zanidatamab |
ZANIDATAMAB (澤尼達妥單抗 ) |
2169946-15-8 |
詳細
|
| Amivantamab |
AMIVANTAMAB (埃萬妥單抗 ) |
2171511-58-1 |
詳細
|
| Axatilimab |
AXATILIMAB (艾克利單抗 ) |
2155851-88-8 |
詳細
|
| Zelminemab |
ZELMINEMAB (澤米奈單抗 ) |
2225850-33-7 |
詳細
|
| Glucocorticoid receptor agonist-1 |
GLUCOCORTICOID RECEPTOR AGONIST-1 |
2166375-82-0 |
詳細
|
| Nec-34i |
2-((3-氰基-6-氧代-4-(對甲苯基)-1,4,5,6-四氫吡啶-2-基)硫基)-N-苯基乙酰胺 |
2212541-00-7 |
詳細
|
| RO7185876 |
(S)-N-[(1R,5S,8S)-3-(6-甲基-4-嘧啶基)-3-氮雜雙環(huán)[3.2.1]辛烷-8-基]-9-(2,3,4-三氟苯基)-6,7,8,9-四氫-5H-[1,2,4]三唑并[1,5-A]氮雜卓-2-胺 |
2226038-71-5 |
詳細
|
| IRAK4-IN-21 |
化合物 IRAK4-IN-21 |
2170694-04-7 |
詳細
|
| Tau-aggregation and neuroinflammation-IN-1 |
化合物 TAU-AGGREGATION AND NEUROINFLAMMATION-IN-1 |
2175953-98-5 |
詳細
|
| MMV688845 |
(R)-GSK1729177A |
2208962-35-8 |
詳細
|
| TZ3O |
化合物 TZ3O |
2218754-19-7 |
詳細
|
| (S)-Desmethyl-NNC112 |
(+)-DESMETHYL-NNC112 |
221132-62-3 |
詳細
|
| Sibrotuzumab |
Sibrotuzumab |
216669-97-5 |
詳細
|
| 2'-O-(2-Azidoethyl)adenosine |
2'-O-(2-Cyanoethyl)adenosine |
2226475-42-7 |
詳細
|
| Relfovetmab |
RELFOVETMAB (瑞弗維單抗 ) |
2171034-70-9 |
詳細
|
| Disitamab |
DISITAMAB (迪西妥單抗 ) |
2185868-98-6 |
詳細
|
| Sasanlimab |
SASANLIMAB (薩善利單抗 ) |
2206792-50-7 |
詳細
|
| Tinurilimab |
替奴瑞利單抗 |
2226224-30-0 |
詳細
|
| SHP2-IN-6 hydrochloride |
SHP2-IN-6 HYDROCHLORIDE |
2169223-49-6 |
詳細
|
| MI-389 |
化合物 T33380 |
2222635-92-7 |
詳細
|
| Ruplizumab |
RUPLIZUMAB |
220651-94-5 |
詳細
|
| Visilizumab |
VISILIZUMAB |
219716-33-3 |
詳細
|
| RO0270608 |
(S)-2-(2-氯-6-甲基苯甲酰氨基)-3-(4-(2,6-二氯苯甲酰氨基)苯基)丙酸 |
220846-33-3 |
詳細
|
| LTβR-IN-1 |
Compound 919278 |
2189366-77-4 |
詳細
|
| Nidanilimab |
NIDANILIMAB (尼達利單抗 ) |
2171061-85-9 |
詳細
|
| Cosibelimab |
COSIBELIMAB (柯希利單抗 ) |
2216751-26-5 |
詳細
|
| MY33-3 |
MY33-3 |
2204280-41-9 |
詳細
|
| AZD8154 |
AZD8154 |
2215022-45-8 |
詳細
|
| Navocaftor |
NAVOCAFTOR |
2159103-66-7 |
詳細
|
| Gemnelatinib |
GEMNELATINIB |
2225123-30-6 |
詳細
|
| (S,R,S)-AHPC-CO-C9-acid |
MDN19780 |
2172819-78-0 |
詳細
|
| INCB-000928 |
化合物 ZILURGISERTIB |
2173389-57-4 |
詳細
|
| Zagociguat |
ZAGOCIGUAT |
2201048-82-8 |
詳細
|
| ATG7-IN-2 |
化合物 ATG7-IN-2 |
2226227-75-2 |
詳細
|
| Pexelizumab |
h5G1.1-scFv |
219685-93-5 |
詳細
|
| Metronidazole-hydroxy-d2 |
羥基甲硝唑-D2 |
2196180-19-3 |
詳細
|
| AKOS037652256 |
N1-(2-(4-(4-chloro-2-fluorophenyl)piperazin-1-yl)phenyl)-N4,N4-dimethylbenzene-1,4-disulfonamide |
2171065-77-1 |
詳細
|
| Lacutamab |
LACUTAMAB (拉可妥單抗 ) |
2187368-16-5 |
詳細
|
| Batoclimab |
巴托利單抗 |
2187430-05-1 |
詳細
|
| PSMA I&T |
PSMA I&T |
2192281-54-0 |
詳細
|
| NV-5440 |
化合物 NV-5440 |
2226614-88-4 |
詳細
|
| MY10 |
化合物 MY10 |
2204270-73-3 |
詳細
|
| Tuberculosis inhibitor 3 |
TUBERCULOSIS INHIBITOR 3 |
2219325-28-5 |
詳細
|
| K-111 |
化合物 T27706 |
221564-97-2 |
詳細
|
| Ragifilimab |
拉格芙利單抗 |
2207590-51-8 |
詳細
|
| (S)-HH2853 |
化合物 (S)-HH2853 |
2202678-05-3 |
詳細
|
| Benproperine |
苯丙哌林 |
2156-27-6 |
詳細
|
| Chst15-IN-1 |
Sulfotransferase-IN-1 |
2158198-77-5 |
詳細
|
| Garadacimab |
GARADACIMAB (加達西單抗 ) |
2162134-62-3 |
詳細
|
| Avdoralimab |
AVDORALIMAB (艾朵利單抗 ) |
2226393-85-5 |
詳細
|
| Nurulimab |
NURULIMAB (諾瑞利單抗 ) |
2168561-20-2 |
詳細
|
| Crobenetine |
克羅奈汀 |
221019-25-6 |
詳細
|
| L 756423 |
化合物 T24362 |
216863-66-0 |
詳細
|
| Benzyl-PEG12-alcohol |
十二甘醇單芐醚 |
2218463-17-1 |
詳細
|
| 4,4-Diphenylbutylamine hydrochloride |
4,4-二苯基丁胺(鹽酸鹽) |
22101-90-2 |
詳細
|
| Indole-C2-amide-C2-NH2 |
化合物 INDOLE-C2-AMIDE-C2-NH2 |
215789-29-0 |
詳細
|
| SARS-CoV-2-IN-14 |
5-氯-N-(3-氯苯基)-2-羥基苯甲酰胺 |
22203-98-1 |
詳細
|
| SOCE inhibitor 1 |
SOCE inhibitor 1 |
2169316-15-6 |
詳細
|
| Semorinemab |
SEMORINEMAB (西瑞奈單抗 ) |
2159141-27-0 |
詳細
|
| Dovanvetmab |
DOVANVETMAB (度伐維單抗 ) |
2171034-71-0 |
詳細
|
| Tafolecimab |
TAFOLECIMAB (托萊西單抗 ) |
2225109-03-3 |
詳細
|
| Thalidomide-O-C6-COOH |
Heptanoic acid, 7-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- |
2169266-69-5 |
詳細
|
| DBCO-PEG3-NHS ester |
二苯并環(huán)辛炔-三聚乙二醇-NHS酯 |
2163772-16-3 |
詳細
|
| MY33-3 hydrochloride |
MY33-3(鹽酸鹽) |
2204280-42-0 |
詳細
|
| Propionanilide, 3'-hydroxy- |
N-(3-HYDROXYPHENYL)PROPANAMIDE |
21556-86-5 |
詳細
|
| Astegolimab |
ASTEGOLIMAB (艾特利單抗 ) |
2173054-79-8 |
詳細
|
| Befovacimab |
BEFOVACIMAB (貝弗西單抗 ) |
2156634-62-5 |
詳細
|
| SCH 57790 |
化合物 T28722 |
221660-80-6 |
詳細
|
| L-796,778 |
化合物 T32511 |
217480-25-6 |
詳細
|
| ALDH1A2-IN-1 |
ALDH1A2-IN-1 |
2204229-64-9 |
詳細
|
| Mal-amide-PEG8-Val-Ala-PAB-PNP |
L-ALANINAMIDE, N-[31-(2,5-DIHYDRO-2,5-DIOXO-1H-PYRROL-1-YL)-1,29-DIOXO-4,7,10,13,16,19,22,25-OCTAOXA-28-AZAHENTRIACONT-1-YL]-L-VALYL-N-[4-[[[(4-NITROPHENOXY)CAR |
2210247-59-7 |
詳細
|
| (R)-HH2853 |
化合物 (R)-HH2853 |
2202678-06-4 |
詳細
|
| PARP10-IN-3 |
化合物PARP10-IN-3 |
2225800-19-9 |
詳細
|
| Mitumomab |
Mitumomab |
216503-58-1 |
詳細
|
| Labetuzumab |
Immunoglobulin G,anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 g-chain), disulfide withhuman-mouse monoclonal hMN-14 k-chain, dimer |
219649-07-7 |
詳細
|
| Monuron-d6 |
滅草隆-D6 |
217488-65-8 |
詳細
|
| Lenalidomide-PEG1-azide |
化合物 LENALIDOMIDE-PEG1-AZIDE |
2185795-67-7 |
詳細
|
| Magrolimab |
MAGROLIMAB (莫洛利單抗 ) |
2169232-81-7 |
詳細
|
| Manelimab |
MANELIMAB (瑪奈利單抗 ) |
2168561-26-8 |
詳細
|
| Atinvicitinib |
1-[(3R,4S)-4-CYANOTETRAHYDRO-2H-PYRAN-3-YL]-3-[(2-FLUORO-6-METHOXY-4-PYRIDINYL)AMINO]-1H-PYRAZOLE-4-CARBOXAMIDE |
2169273-59-8 |
詳細
|
| IRAK4-IN-22 |
化合物 IRAK4-IN-22 |
2170694-05-8 |
詳細
|
| Bamocaftor |
2204245-48-5 |
2204245-48-5 |
詳細
|
| Simazine-d5 |
西瑪津-D5 |
220621-41-0 |
詳細
|
| TLR7 agonist 1 |
TLR7 agonist 1 |
2178156-33-5 |
詳細
|
| Bedinvetmab |
BEDINVETMAB (貝汀維單抗 ) |
2171034-69-6 |
詳細
|
| Encelimab |
ENCELIMAB (安沙利單抗 ) |
2173096-82-5 |
詳細
|
| Arg-Gly-Asp-Cys TFA |
(6S,12S,15R)-1,6-二氨基-12-(羧甲基)-1-亞氨基-15-(巰基甲基)-7,10,13-三氧代-2,8,11,14-四氮雜十六烷-16-酸 三氟乙酸鹽 |
2171504-22-4 |
詳細
|
| TLR7/8-IN-1 |
TLR7/8-IN-1 |
2205095-75-4 |
詳細
|
| Cytembena |
Sodium |
21739-91-3 |
詳細
|
| Elsibucol |
ELSIBUCOL |
216167-95-2 |
詳細
|
| Pramiconazole |
PRAMICONAZOLE |
219923-85-0 |
詳細
|
| Sonlicromanol hydrochloride |
SONLICROMANOL HYDROCHLORIDE |
2162149-24-6 |
詳細
|
| KDM2A/7A-IN-1 |
KDM2A/7A-IN-1 |
2169272-46-0 |
詳細
|
| IL-17A antagonist 1 |
IL-17A antagonist 1 |
2205034-18-8 |
詳細
|
| Petosemtamab |
PETOSEMTAMAB (派森妥單抗 ) |
2213450-26-9 |
詳細
|
| Talquetamab |
塔奎妥單抗 |
2226212-40-2 |
詳細
|
| AVG-233 |
化合物 AVG-233 |
2151937-80-1 |
詳細
|
| (R)-GSK-3685032 |
BENZENEACETAMIDE, Α-[[6-(4-AMINO-1-PIPERIDINYL)-3,5-DICYANO-4-ETHYL-2-PYRIDINYL]THIO]-, (ΑR)- |
2170140-50-6 |
詳細
|